General Proximity

General Proximity is a San Francisco-based biotechnology platform company developing next-generation induced-proximity medicines for traditionally undruggable targets. Its OmniTAC platform enables precise, selective modification of disease-driving proteins, while its unbiased effector-discovery platform identifies powerful proximity mechanisms for specific targets. The company collaborates with research institutions to create highly efficacious proximity therapeutics and expand the reach of medicine through innovative drug discovery.